281 related articles for article (PubMed ID: 28520926)
1. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G
Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926
[TBL] [Abstract][Full Text] [Related]
2. Co-Variation of Peripheral Levels of miR-1202 and Brain Activity and Connectivity During Antidepressant Treatment.
Lopez JP; Pereira F; Richard-Devantoy S; Berlim M; Chachamovich E; Fiori LM; Niola P; Turecki G; Jollant F
Neuropsychopharmacology; 2017 Sep; 42(10):2043-2051. PubMed ID: 28079059
[TBL] [Abstract][Full Text] [Related]
3. Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder.
He S; Liu X; Jiang K; Peng D; Hong W; Fang Y; Qian Y; Yu S; Li H
J Psychiatr Res; 2016 Jul; 78():65-71. PubMed ID: 27078210
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
[No Abstract] [Full Text] [Related]
5. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
[TBL] [Abstract][Full Text] [Related]
6. Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment.
Kim HK; Tyryshkin K; Elmi N; Dharsee M; Evans KR; Good J; Javadi M; McCormack S; Vaccarino AL; Zhang X; Andreazza AC; Feilotter H
J Psychiatr Res; 2019 Mar; 110():38-44. PubMed ID: 30580082
[TBL] [Abstract][Full Text] [Related]
7. Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.
Belzeaux R; Fiori LM; Lopez JP; Boucekine M; Boyer L; Blier P; Farzan F; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Milev R; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Uher R; Foster JA; Kennedy SH; Turecki G
J Clin Psychiatry; 2019 May; 80(3):. PubMed ID: 31087825
[TBL] [Abstract][Full Text] [Related]
8. Aberrant Expression of Intracellular let-7e, miR-146a, and miR-155 Correlates with Severity of Depression in Patients with Major Depressive Disorder and Is Ameliorated after Antidepressant Treatment.
Hung YY; Wu MK; Tsai MC; Huang YL; Kang HY
Cells; 2019 Jun; 8(7):. PubMed ID: 31252530
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine plasma level and antidepressant response.
De Donatis D; Florio V; Porcelli S; Saria A; Mercolini L; Serretti A; Conca A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():127-132. PubMed ID: 30611837
[TBL] [Abstract][Full Text] [Related]
10. BDNF plasma levels variations in major depressed patients receiving duloxetine.
Fornaro M; Escelsior A; Rocchi G; Conio B; Magioncalda P; Marozzi V; Presta A; Sterlini B; Contini P; Amore M; Fornaro P; Martino M
Neurol Sci; 2015 May; 36(5):729-34. PubMed ID: 25501804
[TBL] [Abstract][Full Text] [Related]
11. Using Epigenetic Tools to Investigate Antidepressant Response.
Fiori LM; Lin R; Ju C; Belzeaux R; Turecki G
Prog Mol Biol Transl Sci; 2018; 158():255-272. PubMed ID: 30072056
[TBL] [Abstract][Full Text] [Related]
12. The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder.
Liu W; Zhang F; Zheng Y; He S; Zhang T; Guo Q; Xu H; Chen H; Liu C; Yu S; Jiang K; Li H; Li G; Wang X; Liu X
Neurosci Lett; 2021 Oct; 763():136184. PubMed ID: 34418506
[TBL] [Abstract][Full Text] [Related]
13. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J
World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987
[TBL] [Abstract][Full Text] [Related]
14. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
[TBL] [Abstract][Full Text] [Related]
15. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
[TBL] [Abstract][Full Text] [Related]
16. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
Lam RW; Milev R; Rotzinger S; Andreazza AC; Blier P; Brenner C; Daskalakis ZJ; Dharsee M; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Geraci J; Giacobbe P; Feilotter HE; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; Liotti M; MacQueen GM; McAndrews MP; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Salomons TV; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Kennedy SH;
BMC Psychiatry; 2016 Apr; 16():105. PubMed ID: 27084692
[TBL] [Abstract][Full Text] [Related]
17. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis.
Clayton AH; Hwang E; Kornstein SG; Tourian KA; Cheng RF; Abraham L; Mele L; Boucher M
Int Clin Psychopharmacol; 2015 Nov; 30(6):307-15. PubMed ID: 26230270
[TBL] [Abstract][Full Text] [Related]
18. Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.
Möller HJ; Demyttenaere K; Olausson B; Szamosi J; Wilson E; Hosford D; Dunbar G; Tummala R; Eriksson H
World J Biol Psychiatry; 2015 Oct; 16(7):483-501. PubMed ID: 25602163
[TBL] [Abstract][Full Text] [Related]
19. Predictive socioeconomic and clinical profiles of antidepressant response and remission.
Jain FA; Hunter AM; Brooks JO; Leuchter AF
Depress Anxiety; 2013 Jul; 30(7):624-30. PubMed ID: 23288666
[TBL] [Abstract][Full Text] [Related]
20. MiR-335 is involved in major depression disorder and antidepressant treatment through targeting GRM4.
Li J; Meng H; Cao W; Qiu T
Neurosci Lett; 2015 Oct; 606():167-72. PubMed ID: 26314506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
